CHRS:NSD-Coherus BioSciences, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 14.15

Change

-0.23 (-1.60)%

Market Cap

USD 1.09B

Volume

1.24M

Average Target Price

USD 26.50 (+87.28%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its product candidate pipeline includes biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar; and CHS-131, a once-daily oral drug candidate for non-alcoholic steatohepatitis and other metabolic conditions. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Company Website : http://www.coherus.com

Address : 333 Twin Dolphin Drive, Redwood City, CA, United States, 94065

Employees : 310

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.07

52 Week High : 22.22

Short Ratio : 12.11

52 Week Low : 12.90

Shorted Shares : 10,010,690

200 Day Moving Average : 15.99

Shorted Shares Previous Month : 10,565,200

50 Day Moving Average : 13.94

Shares Held By Insiders : 13.81%

Short Percentage : 13.00%

Shares Held by Institutions : 110.52%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-06-18 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-3.28 (-1.62%)

 USD81.30B 135.70 104.16
REGN Regeneron Pharmaceuticals, Inc

+1.91 (+0.36%)

 USD57.11B 15.26 11.77
BNTX BioNTech SE

-1.78 (-0.83%)

 USD49.23B -99,999.99 35.63
VRTX Vertex Pharmaceuticals Incorpo..

-0.51 (-0.27%)

 USD48.76B 17.95 12.38
ALXN Alexion Pharmaceuticals, Inc

+0.72 (+0.40%)

 USD39.91B 58.41 42.10
BGNE BeiGene, Ltd

-7.33 (-2.23%)

 USD30.29B N/A N/A
GMAB Genmab A/S

-0.61 (-1.40%)

 USD29.17B 26.59 3.71
SGEN Seagen Inc

+2.93 (+1.91%)

 USD27.46B 42.22 39.29
RPRX Royalty Pharma plc

-0.11 (-0.25%)

 USD26.79B 22.60 15.62
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A

ETFs Containing CHRS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -18.58% 28% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -18.58% 28% F 14% F
Trailing 12 Months  
Capital Gain -18.26% 35% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -18.26% 35% F 12% F
Trailing 5 Years  
Capital Gain -9.12% 46% F 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.12% 46% F 20% F
Average Annual (5 Year Horizon)  
Capital Gain -0.75% 31% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.75% 31% F 21% F
Risk Return Profile  
Volatility (Standard Deviation) 37.43% 78% C+ 48% F
Risk Adjusted Return -2.00% 31% F 21% F
Market Capitalization 1.09B 73% C 64% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 8.82 45% F 76% C
Price/Book Ratio 8.37 23% F 18% F
Price / Cash Flow Ratio 7.07 9% F 46% F
EV/EBITDA 5.76 41% F 83% B
Management Effectiveness  
Return on Equity -53.54% 52% F 20% F
Return on Invested Capital 32.45% 94% A 95% A
Return on Assets -5.25% 87% B+ 34% F
Debt to Equity Ratio 134.32% 8% F 15% F
Technical Ratios  
Short Ratio 12.11 17% F 7% F
Short Percent 15.99% 11% F 10% F
Beta 1.07 68% D+ 55% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.